PNC-27
PNC27
Think of it as a guided missile for rogue cells.
PNC-27 is a lab-made peptide that homes in on cancer cells like a heat-seeking missile. It targets a specific protein that's found on the surface of many cancer cells but not on healthy ones. Once it locks on, PNC-27 forms tiny holes in the cancer cell membranes, causing them to break apart and die.
In lab tests, PNC-27 has shown promise in taking down different types of cancer cells, including those from leukemia and breast cancer. It works by sparing healthy cells, which could mean fewer side effects if it ever makes it to human trials. However, it's important to note that PNC-27 is still in the early stages of research and hasn't been tested in humans yet.
Who it's for
- Researchers investigating novel cancer therapies
- Science enthusiasts interested in cutting-edge cancer research
- People curious about potential future cancer treatments
Probably not for you if…
- Anyone looking for a proven cancer treatment
- Those expecting FDA-approved or clinically tested options
- Individuals seeking immediate solutions for cancer therapy
Editorial summary for research context · Not medical advice
Mechanism of Action
PNC-27 is a synthetic chimeric peptide combining residues 12-26 of the p53 protein (the HDM-2 binding region) with a membrane-penetrating leader sequence derived from penetratin. Preclinical research reports that PNC-27 binds HDM-2 that is aberrantly expressed on the surface membrane of cancer cells, forming transmembrane pores that trigger necrotic cell death selectively in malignant cells while sparing normal cells that do not express membrane HDM-2. PNC-27 is strictly a preclinical research compound with no human clinical efficacy data and no FDA approval for any indication.
Researched Benefits
Selective tumor-cell membranolysis (preclinical)
In-vitro studies across multiple human cancer cell lines (leukemia, melanoma, pancreatic, breast) report selective necrosis of malignant cells versus paired normal controls.
- [Michl et al. 2006]
- [Sarafraz-Yazdi et al. 2010]
Xenograft tumor reduction (preclinical)
Mouse xenograft models of pancreatic and acute myeloid leukemia report tumor regression or growth delay with systemic PNC-27 administration.
- [Sarafraz-Yazdi et al. 2015]
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Preclinical research use only
- Dosage
- —
- Frequency
- not established
- Timing
- not established
- Cycle
- —
No validated human dosing exists. All published work is in cell culture and rodent models. This is a preclinical research compound; PNC-27 has not been tested in human clinical trials and should not be used in humans for any therapeutic purpose.
Reported Side Effects
- Human safety profile is unknown — no clinical trial data exist
- Potential for off-target membrane effects in tissues that transiently express HDM-2
- Immunogenicity risk from chimeric peptide (theoretical)
- Injection-site effects (animal data)
Contraindications
- All human use outside a regulated preclinical/IRB-approved investigational setting
- Pregnancy and lactation
- Pediatric use
- Any patient with active medical conditions — no safety data exist
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Gear + Companions
Reconstitution supplies and research-backed supplement companions for PNC-27. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.
Gear you'll need
· Reconstitution + storage essentialsBacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
10:18Urinary System, Part 1: Crash Course Anatomy & Physiology #38
CrashCourse
5.6M views · 10:18 · 10 years ago
19:33The Moment Man Realizes His Scam is Falling Apart - A Body Cam Breakdown
Body Cam Watch
2.1M views · 19:33 · 1 year ago
5:59TIER LIST PEPTIDE EDITION
Greg Doucette
346.2K views · 5:59 · 1 year ago
6:56Doctor Reviews NAD+ vs Peptides - Which Does MORE?
This Is Not Covered - Dr. Ashley Froese
253.1K views · 6:56 · 8 months ago
10:25Homeowners Insurance Exam: Policy Types Overview
Insurance Exam Queen
251.9K views · 10:25 · 4 years ago
Research Papers
PNC-27, a chimeric p53-penetratin peptide, binds to HDM-2 in cancer cell membranes to induce necrosis
Sarafraz-Yazdi E, et al. · Proceedings of the National Academy of Sciences USA · 2010
PubMed 20080731 →Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Michl J, et al. · Proceedings of the National Academy of Sciences USA · 2006
PubMed 17033002 →